UK markets closed

Hyloris Pharmaceuticals SA (HYL.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
17.00-0.45 (-2.58%)
At close: 05:35PM CET
Full screen
Previous close17.45
Open17.55
BidN/A x N/A
AskN/A x N/A
Day's range17.00 - 17.55
52-week range11.02 - 19.10
Volume8,993
Avg. volume11,435
Market cap439.154M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.45
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.33
  • Globe Newswire

    Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis

    Access to AlenuraTM, a dual mode-of-action advanced clinical candidate for the treatment of acute pain in interstitial cystitis/bladder pain syndrome (IC/BPS) Addressable patient population of at least 6 million1 in the U.S. Liège, Belgium – 17 December 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has entered into a strategic collaboration wit

  • Globe Newswire

    Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic® IV

    PDUFA date set on 30 June 2022, ahead of the August to September 2022 timeframe initially expected Liège, Belgium – 15 November 2021, 7:00 am CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the U.S. Food and Drug Administration (FDA) has set the Prescription Drug User Fee Act date (PDUFA) for the New Drug Application (NDA) for Maxigesic® IV on 30 Jun

  • Globe Newswire

    Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer

    Strategic partnership with Pleco Therapeutics for a novel combination product of chelating agents in AML and SCLCHyloris to commit €1 million, convertible into equity, plus pre-defined R&D funding through to regulatory submission Liège, Belgium – 10 November 2021, 7:00am CET – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has entered into a strategic